TNPSC Thervupettagam

Recombinant protein-based COVID-19 vaccine

September 2 , 2021 1055 days 945 0
  • The Reliance Life Sciences (RLS) will be conducting the trials of its recombinant protein-based COVID-19 vaccine candidate.
  • The recombinant protein COVID-19 vaccine uses the spike protein of SARS-CoV-2 as the antigen.
  • This helps the human body to recognize and develop a strong booster response to fight off the COVID-19 infection.

Leave a Reply

Your Comment is awaiting moderation.

Your email address will not be published. Required fields are marked *

Categories